Evidence map›Paper›PMID 39698345›Full record

ReviewKidney international reports2024

Unraveling Diabetic Kidney Disease: The Roles of Mitochondrial Dysfunction and Immunometabolism.

Phoom Narongkiatikhun, Ye Ji Choi, Hailey Hampson, Jimmy Gotzamanis, Guanshi Zhang, Daniel H van Raalte, Ian H de Boer, Robert G Nelson, Kalie L Tommerdahl, Phillip J McCown and 4 more

Abstract readReview
In one paragraph

Review in Kidney international reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. New Insights into the Role of Mitochondrial Dysfunction in Diabetic Kidney Disease in the Omics Era.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
    Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Autophagy and Mitophagy in Diabetic Kidney Disease-A Literature Review.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Phoom NarongkiatikhunDivision of Endocrinology, Department of Medicine, Metabolism and Nutrition, University of Washington School of Medicine, Seattle, Washington, USA.
Ye Ji ChoiDepartment of Pediatrics, Section of Pediatric Endocrinology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Hailey HampsonDivision of Endocrinology, Department of Medicine, Metabolism and Nutrition, University of Washington School of Medicine, Seattle, Washington, USA.
Jimmy GotzamanisINSERM Centre d'Investigation Clinique 1402, CHU Poitiers, University of Poitiers, Poitiers, France.
Guanshi ZhangDepartment of Medicine, Section of Nephrology, University of Texas Health San Antonio, San Antonio, Texas, USA.
Daniel H van RaalteDiabetes Center, Department of Internal Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Ian H de BoerDivision of Nephrology, University of Washington School of Medicine, Seattle, Washington, USA.
Robert G NelsonChronic Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona, USA.
Kalie L TommerdahlDivision of Endocrinology, Department of Medicine, Metabolism and Nutrition, University of Washington School of Medicine, Seattle, Washington, USA.
Phillip J McCownDepartment of Internal Medicine, Division of Nephrology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Jenny KanterDivision of Endocrinology, Department of Medicine, Metabolism and Nutrition, University of Washington School of Medicine, Seattle, Washington, USA.
Kumar SharmaDepartment of Medicine, Section of Nephrology, University of Texas Health San Antonio, San Antonio, Texas, USA.
Petter BjornstadDivision of Endocrinology, Department of Medicine, Metabolism and Nutrition, University of Washington School of Medicine, Seattle, Washington, USA.
Pierre Jean SaulnierINSERM Centre d'Investigation Clinique 1402, CHU Poitiers, University of Poitiers, Poitiers, France.

Funding

Lipid-associated macrophages in diabetic kidney diseaseR01DK121756 · NIDDK · UNIVERSITY OF WASHINGTON · PI Jenny E. Kanter · 2020 to 2026
$2.7M
MANATEE-T1D: Metformin ANd AutomaTEd insulin delivery system Effects on renal vascular resistance, insulin sensitivity, and cardiometabolic function in youth with Type 1 DiabetesK23HL159292 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI TOMMERDAHL, KALIE L · 2021 to 2025
$931k
NHLBI NIH HHS K23 HL159292NHLBI NIH HHS L40 HL159798NIDDK NIH HHS R01 DK121756
6 · The paper itself

Abstract

Mitochondria are essential for cellular energy production and are implicated in numerous diseases, including diabetic kidney disease (DKD). Current evidence indicates that mitochondrial dysfunction results in alterations in several metabolic pathways within kidney cells, thereby contributing to the progression of DKD. Furthermore, mitochondrial dysfunction can engender an inflammatory milieu, leading to the activation and recruitment of immune cells to the kidney tissue, potentially perturbing intrarenal metabolism. In addition, this inflammatory microenvironment has the potential to modify immune cell metabolism, which may further accentuate the immune-mediated kidney injury. This understanding has led to the emerging field of immunometabolism, which views DKD as not just a metabolic disorder caused by hyperglycemia but also one with significant immune contributions. Targeting mitochondrial function and immunometabolism may offer protective effects for the kidneys, complementing current therapies and potentially mitigating the risk of DKD progression. This comprehensive review examines the impact of mitochondrial dysfunction and the potential role of immunometabolism in DKD. We also discuss tools for investigating these mechanisms and propose avenues for integrating this research with existing therapies. These insights underscore the modulation of mitochondrial function and immunometabolism as a critical strategy for decelerating DKD progression.

Indexed as

diabetic kidney diseaseimmunometabolismmetabolic reprogrammingmitochondrial dysfunctionoxidative phosphorylation

Identifiers

PMID39698345
PMCPMC11652104

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.